



Intec Pharma Ltd. Announces Closing of U.S. Initial Public Offering

Har Hotzvim, Jerusalem, Israel, August 7, 2015 – Intec Pharma Ltd. (the “Company”) (NASDAQ: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced the closing of its previously announced initial public offering in the United States of 5,025,000 of its ordinary shares at a price to the public of \$6.00 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 753,750 ordinary shares at the public offering price. At closing, the Company received gross proceeds from the offering of approximately \$30.15 million before deducting underwriting discounts and commissions and other offering expenses. The Company plans to use the net proceeds from the offering to fund its Phase III clinical trial for its current product candidate, Accordion Pill Carbidopa/Levodopa, and its continued development, and for working capital, capital expenditures and other general corporate purposes, including a Phase I clinical trial that the Company expects to initiate in the second half of 2015 for one of its early stage pipeline products.

The Company’s ordinary shares began trading on The NASDAQ Capital Market on August 4, 2015 under the symbol “NTEC”.

Maxim Group LLC and Roth Capital Partners acted as joint book-running managers for the offering.

Investors may obtain the Company’s documents filed with the Securities and Exchange Commission at no cost by visiting the SEC’s website at <http://www.sec.gov>.